A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.

被引：0
|
作者：
McWhirter, Elaine
Hamid, Omid
Chmielowski, Bartosz
Carvajal, Richard D.
Jaffray, David A.
Driscoll, Brandon
Shek, Tina
Yeung, Ivan
Keller, Harald
McKee, Trevor D.
Pearce, Tillman E.
Kroll, Stew
Joshua, Anthony M.
机构：
[1] Juravinski Canc Ctr, Hamilton, ON, Canada
[2] Angeles Clin & Res Inst, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Los Angeles, CA USA
[4] Columbia Univ, Med Ctr, New York, NY USA
[5] Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Threshold Pharmaceut Inc, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9089
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study
    Choong-kun Lee
    Jii Bum Lee
    Se Jung Park
    Jingmin Che
    Woo Sun Kwon
    Hyo Song Kim
    Minkyu Jung
    Seulkee Lee
    Sook Ryun Park
    Dong-Hoe Koo
    Hyun Woo Lee
    Woo Kyun Bae
    Hei-Cheul Jeung
    In Gyu Hwang
    Hyunki Kim
    Chung Mo Nam
    Hyun Cheol Chung
    Sun Young Rha
    Gastric Cancer, 2024, 27 : 118 - 130
  • [42] Preliminary safety and efficacy of evofosfamide (TH-302), an investigational hypoxia-activated prodrug, combined with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RR MM).
    Laubach, Jacob
    Raje, Noopur S.
    Yee, Andrew Jenho
    Armand, Philippe
    Schlossman, Robert L.
    Rosenblatt, Jacalyn
    Hedlund, Jacquelyn Ann
    Martin, Michael Gary
    Reynolds, Craig H.
    Shain, Kenneth H.
    Zackon, Ira
    Stampleman, Laura
    Boswell, Erica
    Chuma, Stacey
    Liguori, Rebecca
    Handisides, Damian
    Kroll, Stew
    Anderson, Kenneth Carl
    Richardson, Paul G.
    Ghobrial, Irene M.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
    Brenner, Andrew J.
    Floyd, John
    Fichtel, Lisa
    Michalek, Joel
    Kanakia, Kunal P.
    Huang, Shiliang
    Reardon, David
    Wen, Patrick Y.
    Lee, Eudocia Quant
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [44] EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, FINAL RESULTS OF A MULTICENTER PHASE II STUDY
    Brenner, Andrew J.
    Reardon, David
    Wen, Patrick
    Huang, Shiliang
    Fox, Peter
    Muzi, Mark
    Lee, Eudocia
    NEURO-ONCOLOGY, 2018, 20 : 14 - 15
  • [45] HYPOXIA ACTIVATED EVOPHOSPHAMIDE (TH-302) FOR RECURRENT GBM FOLLOWING BEVACIZUMAB FAILURE, A MULTICENTER PHASE II STUDY
    Brenner, Andrew
    Reardon, David
    Wen, Patrick
    Fox, Peter
    Huang, Shiliang
    Muzi, Mark
    Liu, Yichu
    Lee, Eudocia
    NEURO-ONCOLOGY, 2017, 19 : 21 - 21
  • [46] Integrated biomarker study of neoadjuvant pepinemab and nivolumab in patients with resectable metastatic melanoma.
    Lowe, Michael C.
    Olson, Brian
    Martinez, Anthony
    Hammons, Jacklyn
    Delman, Keith A.
    Yushak, Melinda Lynne
    Allor, Melanie
    Reilly, Christine A.
    Mallow, Crystal L.
    Evans, Elizabeth E.
    Fisher, Terrence Lee
    Lesinski, Gregory B.
    Kudchadkar, Ragini Reiney
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer
    Borad, M. J.
    Reddy, S.
    Uronis, H.
    Sigal, D. S.
    Cohn, A. L.
    Schelman, W. R.
    Stephenson, J.
    Chiorean, E. G.
    Rosen, P. J.
    Ulrich, B.
    Dragovich, T.
    Del Prete, S.
    Rarick, M.
    Eng, C.
    Kroll, S.
    Ryan, D.
    CANCER RESEARCH, 2012, 72
  • [48] A phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with advanced melanoma.
    Shaikh, Saba
    Zang, Yan
    Hanmer, Janel
    Wang, Hong
    Lin, Yan
    Davar, Diwakar
    Zarour, Hassane M.
    Kirkwood, John M.
    Najjar, Yana G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] A phase I trial of riluzole and sorafenib in patients with advanced solid tumors and melanoma.
    Mehnert, Janice M.
    Semlani, Neha
    Wen, Yvonne
    Tan, Antoinette R.
    Moss, Rebecca Anne
    Adams, Shari
    Stein, Mark N.
    Ross, Mikel
    Kane, Michael P.
    Gibbon, Darlene
    Wright, John Joseph
    Aisner, Joseph
    Chen, Suzie
    Goydos, James S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF EVOFOSFAMIDE (TH-302) IN COMBINATION WITH PEMETREXED IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Goldman, J.
    Belani, C.
    Novello, S.
    von Pawel, J.
    Csoszi, T.
    Orlov, S.
    Kroll, S.
    Pearce, T.
    ANNALS OF ONCOLOGY, 2015, 26
12345